Both of the organisms in NARAMUNE-2 are avirulent so
that they can be safely administered intranasally with little or no
symptoms of disease. By instilling these organisms into the nasal
passages, it becomes possible for these agents to infect target cells of
the nasal-pharyngeal region, mimicking the pathogenesis of natural
field infection. A very small percentage of dogs may show sneezing,
coughing or nasal discharge for 3-10 days following vaccination. While
these are usually temporary symptoms, antibacterial therapy may be
Dosage and Administration:
Rehydration: Rehydrate to desired dose volume with accompanying sterile
diluent. For five 0.5 mL doses, reconstitute with 2.5 mL of diluent. For
five 1 mL doses, reconstitute with 5 mL of diluent. Shake well and use
Using aseptic technique, administer entire dose
intranasally. Use enclosed applicator tip on hub of syringe in place of
syringe needle. Apply new nasal applicator tip for each dog vaccinated.
Do not vaccinate puppies under 3 weeks of age. Puppies vaccinated
between 3 and 6 weeks of age should be revaccinated at 6 weeks of age.
Annual revaccination is recommended.
Precaution(s): Store out of direct
sunlight at a temperature between 35-45°F (2-7°C). Use entire contents
when first opened. Burn containers and all unused contents.
Caution(s): For intranasal use in dogs only; do not vaccinate dogs parenterally. Anaphylactoid reactions may occur.